How many biomarker measurements are needed to predict prognosis in Crohn's disease patients under infliximab?-A prospective study.
Fiche publication
Date publication
juin 2023
Journal
United European gastroenterology journal
Auteurs
Membres identifiés du Cancéropôle Est :
Pr PEYRIN-BIROULET Laurent
Tous les auteurs :
Magro F, Estevinho MM, Catalano G, Patita M, Arroja B, Lago P, Rosa I, Tavares de Sousa H, Ministro P, Mocanu I, Vieira A, Castela J, Moleiro J, Roseira J, Cancela E, Sousa P, Portela F, Correia L, Moreira P, Santiago M, Dias S, Afonso J, Danese S, Peyrin-Biroulet L, Dias CC,
Lien Pubmed
Résumé
Timely stratification of Crohn's disease (CD) is essential for patients' management. The use of noninvasive accurate biomarkers is key to monitor treatment and to pursue mucosal healing, the ultimate treatment endpoint in CD.
Mots clés
Crohn's disease, biomarkers, calprotectin, infliximab
Référence
United European Gastroenterol J. 2023 06 15;: